Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CarVin versus CarEto in small cell lung cancer
ISRCTN44486227Phase 2Terminated
- Sponsor
- United States Department of Health and Human Services
- Start
- Apr 2002
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of carboplatin, vinorelbine and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by United States Department of Health and Human Services. Primary endpoints: Toxicity and Tumour response. Started Apr 2002; status: terminated.
02
Drugs
carboplatinvinorelbineetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ISRCTN44486227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44486227.